You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|
|---|---|
| Published in |
Journal of Hematology & Oncology, March 2016
|
| DOI | 10.1186/s13045-016-0250-9 |
| Pubmed ID | |
| Authors |
Jingjing Wu, Mingzhi Zhang, Delong Liu |
| Abstract |
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 60% |
| Thailand | 1 | 20% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 193 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | <1% |
| Unknown | 192 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 30 | 16% |
| Student > Ph. D. Student | 29 | 15% |
| Student > Bachelor | 28 | 15% |
| Student > Master | 20 | 10% |
| Other | 14 | 7% |
| Other | 31 | 16% |
| Unknown | 41 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 20% |
| Chemistry | 34 | 18% |
| Biochemistry, Genetics and Molecular Biology | 26 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 21 | 11% |
| Agricultural and Biological Sciences | 12 | 6% |
| Other | 17 | 9% |
| Unknown | 45 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 July 2022.
All research outputs
#1,378,116
of 25,391,066 outputs
Outputs from Journal of Hematology & Oncology
#76
of 1,290 outputs
Outputs of similar age
#22,808
of 312,604 outputs
Outputs of similar age from Journal of Hematology & Oncology
#1
of 33 outputs
Altmetric has tracked 25,391,066 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,290 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.4. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,604 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.